Latanoprost Aurobindo (Latanoprost)

Latanoprost is a prostaglandin F2α analog that binds to FP receptors in the ciliary body, enhancing uveoscleral outflow of aqueous humor. The increased outflow reduces intra‑ocular pressure, addressing the primary pathogenic factor in open‑angle glaucoma and ocular hypertension.

The dosing regimen is determined by the prescribing eye‑care professional. Typically, one drop is instilled in the affected eye(s) once daily in the evening, but the exact dose and timing are individualized based on patient response and clinical judgment.

Safety data for latanoprost during pregnancy and lactation are limited. The product is classified as pregnancy category unknown; therefore it should only be used when the potential benefit justifies any potential risk to the fetus or infant, and under medical supervision.

Enquiries can be submitted through the product page on gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with beta‑blocker eye drops, latanoprost generally provides greater intra‑ocular pressure reduction with once‑daily dosing and a different side‑effect profile, such as increased eyelash growth. Unlike carbonic anhydrase inhibitors, it does not affect systemic carbonic anhydrase activity, reducing systemic adverse events.

Latanoprost Aurobindo should be stored at room temperature, below 25 °C, in the original container. Protect the bottle from light and moisture, and keep the cap tightly closed. Do not freeze the solution; discard any product that appears discolored or contaminated.

The patient should wash hands, tilt the head back, and gently pull down the lower eyelid to create a pocket. One drop is placed into the conjunctival sac without touching the tip to the eye or lashes. Close the eye gently for a few minutes and avoid excessive blinking.

Although rare, serious adverse events can include severe allergic reactions, uveitis, or corneal edema, which may threaten vision. Patients should seek immediate medical attention if they experience intense eye pain, sudden vision loss, swelling, or signs of an allergic response such as rash or eyelid swelling.

Individuals with known hypersensitivity to latanoprost or any component of the formulation should avoid its use. It is also contraindicated in eyes with active intra‑ocular inflammation, infection, or in patients who have had recent ocular surgery until cleared by an ophthalmologist.